Venous Thromboembolism – Landscape & Forecast – Disease Landscape & Forecast
Copy/Paste the core content from the latest edited report brochure. DELETE the “Market Outlook” header from the top.
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the location of the obstruction. Pharmacological treatment of patients diagnosed with VTE consists mainly of anticoagulant therapy and, in some severe cases, thrombolytics. Patients at high risk of VTE receive primary prophylaxis with anticoagulants. These patients include hospitalized medically ill patients, patients undergoing orthopedic surgery or non-orthopedic surgery, and cancer patients. In recent years, new oral anticoagulants (NOACs) have become more widely used and have driven the growth of the VTE market. These drugs are being investigated to broaden their target population and to cover specific segments, while emerging therapies in the VTE pipeline include Novartis’s abemaciclib and Bayer’s osocimab (both are human monoclonal antibodies), Bristol Myers Squibb’s milvexian, Translational Sciences’ TS23, and Ionis’s fesomersen.
Questions answered
- What are the key drivers and goals of VTE treatment? How do current therapies perform on these goals?
- What do key opinion leaders think about Novartis’s abemaciclib, Bayer’s osocimab, Bristol Myers Squibb’s milvexian, Translational Sciences’ TS23, and Ionis’s fesomersen?
- Will label expansions and genericization affect the market?
- What are the key unmet needs in VTE, and how likely are they to be met?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Venous Thromboembolism - Landscape & Forecast - Disease Landscape & Forecast
- Key updates
- A note about this report
- Q2 2023
- June 2023
- Key findings
- Venous thromboembolism key findings - June 2023
- June 2023
- Venous thromboembolism key findings - June 2023
- Market outlook
- Key findings
- Market share of drug classes for diagnosed events of VTE: 2022
- Market share of drug classes for diagnosed events of VTE: 2032
- Market share of drug classes for surgical and nonsurgical hospitalizations eligible for VTE acute prophylaxis: 2022
- Market share of drug classes for surgical and nonsurgical hospitalizations eligible for VTE acute prophylaxis: 2032
- Market share of drug classes for diagnosed prevalence of cancer patients eligible for VTE prophylaxis: 2022
- Market share of drug classes for diagnosed prevalence of cancer patients eligible for VTE prophylaxis: 2032
- Venous thromboembolism SWOT analysis
- Market drivers and constraints
- What factors are driving the market for venous thromboembolism?
- What factors are constraining the market for venous thromboembolism?
- Annual sales for total VTE by segments in the major pharmaceutical markets: 2022-2032
- Segment-specific trends
- Major-market annual patient share by drug for diagnosed events of VTE: 2022-2032
- Major-market annual sales by drug for diagnosed events of VTE: 2022-2032
- Major-market annual patient share by drug for surgical and nonsurgical hospitalizations eligible for VTE acute prophylaxis: 2022-2032
- Major-market annual sales by drug for surgical and nonsurgical hospitalizations eligible for VTE acute prophylaxis: 2022-2032
- Major-market annual patient share by drug for cancer patients eligible for VTE prophylaxis: 2022-2032
- Major-market annual sales by drug for cancer patients eligible for VTE prophylaxis: 2022-2032
- Key findings
- Forecast
- Market forecast assumptions: diagnosed events of venous thromboembolism
- Market forecast assumptions: surgical and nonsurgical hospitalizations eligible for VTE acute prophylaxis
- Market forecast assumptions: diagnosed prevalence of cancer patients eligible for VTE prophylaxis
- Market forecast dashboard: diagnosed events of venous thromboembolism
- Market forecast dashboard: surgical and nonsurgical hospitalizations eligible for VTE acute prophylaxis
- Market forecast dashboard: diagnosed prevalence of cancer patients eligible for VTE prophylaxis
- Etiology and pathophysiology
- Disease overview
- Development of deep vein thrombosis and pulmonary embolism
- Veins of the lower extremities involved in deep vein thrombosis
- Disease pathophysiology
- Virchow's triad and associated factors
- Vascular endothelial injury
- Tissue factor exposure, expression, and localization
- Venous stasis
- Hypercoagulability: prothrombotic state
- The coagulation process
- The cascade model
- The cell-based model
- The cascade model of coagulation
- The coagulation cascade and mechanism of action of anticoagulant agents
- The cell-based model of coagulation
- Venous thromboembolism risk factors
- Key pathways and drug targets
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods
- Sources used to estimate the diagnosed events of venous thromboembolism.
- Number of diagnosed events of venous thromboembolism: 2022-2032
- Disease definition
- Methods
- Sources used to estimate the number of surgical and nonsurgical hospitalizations eligible for VTE acute prophylaxis
- Number of surgical and nonsurgical hospitalizations eligible for VTE acute prophylaxis: 2022-2032
- Disease definition
- Methods
- Sources used to estimate the number of diagnosed prevalence of cancer patients eligible for VTE prophylaxis
- Number of diagnosed prevalent cases of cancer patients eligible for VTE prophylaxis: 2022-2032
- Drug-treated cases of diagnosed VTE events: 2022-2032
- Drug-treated cases of surgical and nonsurgical hospitalizations eligible for VTE acute prophylaxis: 2022-2032
- Drug-treated cases of diagnosed prevalent cases of cancer patients eligible for VTE prophylaxis: 2022-2032
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for venous thromboembolism
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for venous thromboembolism
- Current treatments used for venous thromboembolism
- Market events impacting the use of key current therapies for venous thromboembolism
- Advantages and disadvantages of vitamin K antagonists
- Expert insight: vitamin K antagonists
- Advantages and disadvantages of unfractioned heparin
- Advantages and disadvantages of low-molecular-weight heparin
- Ongoing clinical development of heparins and heparinoids
- Key ongoing clinical trials of heparins and heparinoids in the treatment of venous thromboembolism
- Expert insight: heparins and heparinoids
- Advantages and disadvantages of indirect FXa inhibitors
- Expert insight: indirect FXa inhibitors
- Oral direct FXa inhibitors
- Rivaroxaban
- Advantages and disadvantages of rivaroxaban
- Key results from select clinical trials investigating rivaroxaban for the treatment of venous thromboembolism
- Key ongoing clinical trials of rivaroxaban in the treatment of venous thromboembolism
- Expert insight: rivaroxaban
- Apixaban
- Advantages and disadvantages of apixaban
- Key results from select clinical trials investigating apixaban for the treatment of venous thromboembolism
- Ongoing clinical development of apixaban
- Key ongoing clinical trials of apixaban in the treatment of venous thromboembolism
- Expert insight: apixaban
- Edoxaban
- Advantages and disadvantages of edoxaban
- Key results from select clinical trials investigating edoxaban for the treatment of venous thromboembolism
- Expert insight: edoxaban
- Argatroban
- Advantages and disadvantages of argatroban
- Expert insight: argatroban
- Dabigatran etexilate mesylate
- Advantages and disadvantages of dabigatran etexilate mesylate
- Expert insight: dabigatran etexilate mesylate
- Thrombolytics
- Advantages and disadvantages of thrombolytics
- Expert insight: thrombolytics
- Acetylsalicylic acid (aspirin)
- Advantages and disadvantages of aspirin
- Expert insight: aspirin
- Medical practice
- Overview
- Factors influencing drug selection in venous thromboembolism
- Treatment decision tree for venous thromboembolism: United States
- Treatment decision tree for venous thromboembolism: Europe
- Treatment decision tree for venous thromboembolism: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in venous thromboembolism
- Top unmet needs in venous thromboembolism: current and future attainment
- Expert insight: unmet need in venous thromboembolism
- Drug pipeline
- Pipeline
- Regulatory milestones
- Indication comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for venous thromboembolism
- Estimated launch dates of key emerging therapies for the treatment of venous thromboembolism
- Factor XI inhibitors
- Key results of select clinical trials investigating abelacimab for the treatment of venous thromboembolism
- Key ongoing clinical trials of abelacimab in the treatment of venous thromboembolism
- Analysis of the clinical development program for abelacimab
- Expert insight: abelacimab
- Expectations for launch and sales opportunity of abelacimab in venous thromboembolism
- Key results of select clinical trials investigating milvexian for the prevention of venous thromboembolism
- Analysis of the clinical development program for milvexian
- Expert insight: milvexian
- Expectations for launch and sales opportunity of milvexian in venous thromboembolism
- Key results of select clinical trials investigating fesomersen for the prevention of venous thromboembolism
- Analysis of the clinical development program for fesomersen
- Expert insight: fesomersen
- Expectations for launch and sales opportunity of fesomersen in venous thromboembolism
- Key results of select clinical trials investigating osocimab for the prevention of venous thromboembolism
- Analysis of the clinical development program for osocimab
- Expectations for launch and sales opportunity of osocimab in venous thromboembolism
- Key results of select clinical trials investigating TS23 for the treatment of venous thromboembolism
- Key ongoing clinical trials of TS23 in the treatment of venous thromboembolism
- Analysis of the clinical development program for TS23
- Expert insight: TS23
- Expectations for launch and sales opportunity of TS23 in venous thromboembolism
- Early-phase pipeline analysis
- Select compounds in early-phase development for venous thromboembolism
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in venous thromboembolism: United States
- General reimbursement environment: United States
- Key market access considerations in venous thromboembolism: EU5
- General reimbursement environment: EU5
- Key market access considerations in venous thromboembolism: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Venous thromboembolism bibliography
- Key updates
Laia Martínez-Carreres, M.Sc., Ph.D., Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematological Disorders. Dr. Martinez-Carreres has authored reports on polycystic kidney disease, venous thromboembolism, and atrial fibrillation. Prior to joining Clarivate, she was a clinical research project manager at Parc Taulí Hospital (Spain). She holds a Ph.D. in biomedical sciences from the University of Lausanne, where she studied the role of the cell cycle-related protein CDK4 in metabolism in the laboratory of Professor Lluis Fajas. She also holds a master’s degree in translational medicine and a bachelor’s degree in biomedical sciences, both from the University of Barcelona. Dr. Martínez-Carreres also trained as a data analyst at EADA Business School in Spain.